{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:25:23Z","timestamp":1759541123705,"version":"3.43.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,7]]},"DOI":"10.7759\/cureus.89569","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T01:25:07Z","timestamp":1754616307000},"source":"Crossref","is-referenced-by-count":1,"title":["Hyperparathyroidism Secondary to Burosumab Treatment"],"prefix":"10.7759","author":[{"given":"Minhtri K","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhiresh","family":"Bandaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minh-Kevin","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0587","article-title":"The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases","volume":"64","author":"Feng J","year":"2017","unstructured":"Feng J, Jiang Y, Wang O, et al.. The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocr J. 2017, 64:675-83. 10.1507\/endocrj.EJ16-0587","journal-title":"Endocr J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00691-6","article-title":"Tumor-induced osteomalacia","volume":"108","author":"Florenzano P","year":"2021","unstructured":"Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT. Tumor-induced osteomalacia. Calcif Tissue Int. 2021, 108:128-42. 10.1007\/s00223-020-00691-6","journal-title":"Calcif Tissue Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0006","article-title":"Tumor-induced osteomalacia","volume":"18","author":"Chong WH","year":"2011","unstructured":"Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011, 18:R53-77. 10.1530\/ERC-11-0006","journal-title":"Endocr Relat Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab099","article-title":"Diagnosis and management of tumor-induced osteomalacia: perspectives from clinical experience","volume":"5","author":"Dahir K","year":"2021","unstructured":"Dahir K, Zanchetta MB, Stanciu I, et al.. Diagnosis and management of tumor-induced osteomalacia: perspectives from clinical experience. J Endocr Soc. 2021, 5:bvab099. 10.1210\/jendso\/bvab099","journal-title":"J Endocr Soc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007010068","article-title":"How fibroblast growth factor 23 works","volume":"18","author":"Liu S","year":"2007","unstructured":"Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007, 18:1637-47. 10.1681\/ASN.2007010068","journal-title":"J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.20223311S1659a","article-title":"Frustratingly frail: following the phosphorous","volume":"33","author":"Giehl NM","year":"2022","unstructured":"Giehl NM, Nguyen MK. Frustratingly frail: following the phosphorous. J Am Soc Nephrol. 2022, 33:659.","journal-title":"J Am Soc Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2023.07.108","article-title":"Hyperparathyroidism after 3 years of burosumab in children affected with X-linked hypophosphatemia","volume":"84","author":"Zhukouskaya V","year":"2023","unstructured":"Zhukouskaya V, Ertl A, Berkenou J, et al.. Hyperparathyroidism after 3 years of burosumab in children affected with X-linked hypophosphatemia. Ann Endocrinol (Paris). 2023, 84:544. 10.1016\/j.ando.2023.07.108","journal-title":"Ann Endocrinol (Paris)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/biom13081222","article-title":"Relationship of fibroblast growth factor 23 serum levels with disease characteristics in systemic lupus erythematosus patients","volume":"13","author":"Fern\u00e1ndez-Cladera Y","year":"2023","unstructured":"Fern\u00e1ndez-Cladera Y, G\u00f3mez-Bernal F, Garc\u00eda-Gonz\u00e1lez M, et al.. Relationship of fibroblast growth factor 23 serum levels with disease characteristics in systemic lupus erythematosus patients. Biomolecules. 2023, 13:1222. 10.3390\/biom13081222","journal-title":"Biomolecules"},{"key":"ref9","unstructured":"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD). (2024). Accessed. n.d: https:\/\/www.medilib.ir\/uptodate\/show\/1969."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32409","article-title":"The parathyroid is a target organ for FGF23 in rats","volume":"117","author":"Ben-Dov IZ","year":"2007","unstructured":"Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al.. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007, 117:4003-8. 10.1172\/JCI32409","journal-title":"J Clin Invest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/srep40534","article-title":"Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease","volume":"7","author":"Kawakami K","year":"2017","unstructured":"Kawakami K, Takeshita A, Furushima K, et al.. Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease. Sci Rep. 2017, 7:40534. 10.1038\/srep40534","journal-title":"Sci Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009040427","article-title":"FGF23 fails to inhibit uremic parathyroid glands","volume":"21","author":"Canalejo R","year":"2010","unstructured":"Canalejo R, Canalejo A, Martinez-Moreno JM, et al.. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol. 2010, 21:1125-35. 10.1681\/ASN.2009040427","journal-title":"J Am Soc Nephrol"},{"key":"ref13","unstructured":"Understand the important safety information for CRYSVITA. (n.d). https.\/\/www.crysvita.com\/tio\/safety-information\/."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac650","article-title":"Hyperparathyroidism in a large cohort of Chinese patients with tumor-induced osteomalacia","volume":"108","author":"Ni X","year":"2023","unstructured":"Ni X, Liu W, Zhang D, et al.. Hyperparathyroidism in a large cohort of Chinese patients with tumor-induced osteomalacia. J Clin Endocrinol Metab. 2023, 108:1224-35. 10.1210\/clinem\/dgac650","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/376687-hyperparathyroidism-secondary-to-burosumab-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T01:25:10Z","timestamp":1754616310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/376687-hyperparathyroidism-secondary-to-burosumab-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.89569","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,7]]}}}